GSK Gains Rights to Janssen’s Hepatitis B Therapy JNJ-3989 for US$1 B
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)
Published: 3 Nov-2023
DOI: 10.3833/pdr.v2023.i11.2835 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
To advance the development of its chronic hepatitis B (CHB) therapies, GSK has entered into a licensing agreement with Janssen Pharmaceuticals for exclusive worldwide rights to JNJ-3989, a small interfering ribonucleic acid (siRNA) therapeutic for CHB, originally in-licensed by Janssen from Arrowhead Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS